ArticleMultidisciplinary respiratory medicine2018
Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries.
Article in Multidisciplinary respiratory medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Development of a Novel Biomarker for the Progression of Idiopathic Pulmonary Fibrosis.International journal of molecular sciences · 2024Article
- A scoping review of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis (IPF).PloS one · 2024Article
- Overall drug treatment of idiopathic pulmonary fibrosis patients from national registries - a real-world study from Finland.BMC pulmonary medicine · 2023Article
- Disparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary Fibrosis.Chest · 2023Article
- Exploration of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis: a scoping review protocol.BMJ open · 2023Article
- Investigation of clinical predictors of survival in idiopathic pulmonary fibrosis patients: A cohort study in Taiwan.Journal of the Chinese Medical Association : JCMA · 2022Article
- Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.Respiratory research · 2021Article
- Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study.Respiratory research · 2021Observational
- Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry.Respiratory research · 2021Article
- Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry.Annals of the American Thoracic Society · 2020Article
- Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality.European clinical respiratory journal · 2020Article
- Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.Respiratory research · 2020Review
- Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.Respiratory research · 2019Review
- Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry.ERJ open research · 2019Article
- Antifibrotic drug treatment of patients with idiopathic pulmonary fibrosis in Sweden: A registry-based observational study.Chronic respiratory diseaseObservational
- Beyond Chronological Age: Aging and Senescence in Interstitial Lung Diseases.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung function with high mortality within the first 5 years from diagnosis. In 2011-2014, two drugs, pirfenidone and nintedanib, have been approved worldwide for prevention of IPF progression. National IPF-registries have been established in both Finland and Sweden. Our study explored potential differences in the care of IPF in these two countries.
methodsPatients included consecutively in the Finnish and Swedish IPF-registries from January 1, 2014 through December 31, 2016 were included in the study. Data on demographics and lung function at the time of inclusion were collected. Access to antifibrotic drugs and data on disease outcomes, mortality and the proportion of patients who underwent lung transplantation, was collected during a 3-year follow up.
resultsOne-hundred and fifty-two patients from the Finnish and 160 patients from the Swedish IPF-cohorts were included in the study. At inclusion, Finnish patients were significantly older than the Swedish patients (74.6 years vs 72.5 years,
conclusionsThis study highlights differences concerning how IPF patients are treated in Finland and Sweden. How these differences will influence the long-term outcome of these patients is unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.